Advertisement
Advertisement
Trending on Urology Times
1
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
2
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
3
Pedro Barata, MD, highlights phase 3 data on 177Lu-rosopatamab tetraxetan in mCRPC
4
PROTEUS: Apalutamide plus ADT before and after RP cuts metastasis risk
5